Browsing by Author "Cheifetz, Adam"
Now showing items 1-12 of 12
-
Attitudes to Mesalamine Questionnaire: A Novel Tool to Predict Mesalamine Nonadherence in Patients with IBD
Moss, Alan C; Lillis, Yvonne; Edwards George, Jessica B.; Choudhry, Niteesh Kumar; Berg, Anders Hayden; Cheifetz, Adam S.; Horowitz, Gary Leigh; Leffler, Daniel Alexander (Springer Nature, 2014)OBJECTIVES: Poor adherence to mesalamine is common and driven by a combination of lifestyle and behavioral factors, as well as health beliefs. We sought to develop a valid tool to identify barriers to patient adherence and ... -
Biologic Concentration Testing in Inflammatory Bowel Disease
Vaughn, Byron P.; Sandborn, William J.; Cheifetz, Adam S. (Lippincott Williams & Wilkins, 2015)Abstract: Anti-TNF medications have revolutionized the care of patients with inflammatory bowel disease. However, despite an initial robust effect, loss of response is common and long-term results are disappointing. Much ... -
CD39 and CD161 Modulate Th17 Responses in Crohn's Disease
Bai, Aiping; Moss, Alan; Kokkotou, Efi; Usheva, Anny; Sun, Xiaofeng; Cheifetz, Adam; Zheng, Yi; Longhi, Maria Serena; Gao, Wenda; Wu, Yan; Robson, Simon (The American Association of Immunologists, 2014-08-29)CD39 (ENTPD1) is expressed by subsets of pathogenic human CD4+ T cells, such as T helper type 17 (Th17) cells. These Th17 cells are considered important in intestinal inflammation, such as seen in Crohn’s disease. Recently, ... -
CD73 Is a Phenotypic Marker of Effector Memory Th17 Cells in Inflammatory Bowel Disease
Doherty, Glen; Bai, Aiping; Hanidziar, Dusan; Longhi, Maria Serena; Lawlor, Garrett; Putheti, Prabhakar; Csizmadia, Eva; Nowak, Martina; Cheifetz, Adam; Moss, Alan; Robson, Simon (Wiley, 2012-10-29)Purinergic signaling and associated ectonucleotidases, such as CD39 and CD73, have been implicated in the pathogenesis of inflammatory bowel disease (IBD). CD39 is known to be a Treg memory cell marker, and here we determine ... -
Characterization of Human CD39+ Th17 Cells with Suppressor Activity and Modulation in Inflammatory Bowel Disease
Longhi, Maria Serena; Moss, Alan; Bai, Aiping; Wu, Yan; Huang, Huang; Cheifetz, Adam; Quintana, Francisco J.; Robson, Simon C. (Public Library of Science, 2014)Induced regulatory T-cells (iT-reg) and T helper type 17 (Th17) in the mouse share common CD4 progenitor cells and exhibit overlapping phenotypic and functional features. Here, we show that human Th17 cells endowed with ... -
Comparative Cost-Effectiveness of Strategies to Prevent Postoperative Clinical Recurrence of Crohnʼs Disease
Doherty, Glen; Miksad, Rebecca A.; Cheifetz, Adam; Moss, Alan C. (Oxford University Press (OUP), 2012-09-01)Background A number of treatments have been shown to reduce the risk of postoperative recurrence of Crohn's disease (CD). The optimal strategy is unknown. The aim was to evaluate the comparative cost-effectiveness of ... -
Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients with Inflammatory Bowel Disease (IBD): A Meta-Analysis
Nanda, Kavinderjit S.; Cheifetz, Adam; Moss, Alan C. (Ovid Technologies (Wolters Kluwer Health), 2013-01)OBJECTIVES Antibodies to infliximab (ATIs) have been associated with loss of clinical response and lower serum infliximab (IFX) levels in some studies of patients with inflammatory bowel disease (IBD). This has important ... -
Lectin-Reactive Anti-α-Gal in Patients with Crohnʼs Disease: Correlation with Clinical Phenotypes
Safaie, Parham; Ham, Maggie; Kuang, Peter; Mehta, Anand S.; Wang, Mengjun; Cheifetz, Adam; Robson, Simon; Lau, Daryl; Block, Timothy M.; Moss, Alan C. (Oxford University Press (OUP), 2013-12-01)Background Patients with inflammatory bowel disease have higher proportions of immunoglobulin G (IgG) antibodies lacking N-galactose, also called agalactosyl IgG, in their serum. Such agalactosyl IgGs have been associated ... -
Predictors of Endoscopic Inflammation in Patients with Ulcerative Colitis in Clinical Remission
Rosenberg, Laura; Lawlor, Garreth O.; Zenlea, Talia; Goldsmith, Jeffrey; Gifford, Anne; Falchuk, Kenneth; Wolf, Jacqueline; Cheifetz, Adam; Robson, Simon; Moss, Alan C. (Oxford University Press (OUP), 2013-04-01)Objectives Patients with ulcerative colitis (UC) who are in clinical remission may still have underlying endoscopic inflammation, which is associated with inferior clinical outcomes. The goal of this study was to determine ... -
Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis
Feuerstein, Joseph D.; Akbari, Mona; Tapper, Elliot B.; Cheifetz, Adam S. (Hellenic Society of Gastroenterology, 2016)Background: In patients with ulcerative colitis who fail corticosteroids and are treated with rescue therapy (e.g. infliximab or cyclosporine) but fail to respond, salvage therapy with infliximab or cyclosporine can be ... -
The Use of Pharmacological Prophylaxis Against Venous Thromboembolism in Hospitalised Patients With Severe Active Ulcerative Colitis
Pleet, J. L.; Vaughn, Byron P.; Morris, J. A.; Moss, Alan C.; Cheifetz, Adam (Wiley, 2014-05)Background Hospitalised patients with inflammatory bowel disease are 1.5- to 3.5-fold more likely to develop venous thromboembolism compared to controls. Clinical guidelines recommend pharmacological prophylaxis. Aim To ... -
Vitamin D Levels in Adults with Crohnʼs Disease Are Responsive to Disease Activity and Treatment
Brigham, Maggie; Longhi, Maria Serena; Lahiff, Conor; Cheifetz, Adam; Robson, Simon; Moss, Alan C. (Oxford University Press (OUP), 2014-05)Background: Vitamin D deficiency is common in patients with Crohn’s disease (CD), although whether this impairs immune responsiveness, and is related to disease activity per se, remains unclear. We sought to investigate ...